Phase 1 oncology trials and informed consent

Journal of Medical Ethics

Volumn 39, Issue 12, 2013, Pages 761-764

  Miller, Franklin G ^a   Joffe, Steven ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOETHICS; COMPREHENSION; DECISION MAKING; ETHICS; HUMAN; HUMAN EXPERIMENT; INFORMED CONSENT; INTERPERSONAL COMMUNICATION; MEDICAL ETHICS; PHASE 1 CLINICAL TRIAL (TOPIC); PSYCHOLOGY; RESEARCH ETHICS; RESEARCH SUBJECT; STANDARDS;

BIOETHICS; CLINICAL TRIALS, PHASE I AS TOPIC; COMPREHENSION; DECISION MAKING; DISCLOSURE; ETHICS, MEDICAL; ETHICS, RESEARCH; HUMANS; INFORMED CONSENT; NONTHERAPEUTIC HUMAN EXPERIMENTATION; RESEARCH SUBJECTS;

EID: 84890158082     PISSN: 03066800     EISSN: 14734257     Source Type: Journal    
DOI: 10.1136/medethics-2012-100832     Document Type: Article

References (25)

1. Daugherty CK. Ethical issues in the development of new agents. Invest New Drugs 1999;17:145-53.
2. Annas GJ. Questing for grails: duplicity, betrayal and self-deception in postmodern medical research. J Contemp Health Law Policy 1996;12:297-324.
3. Miller M. Phase 1 cancer trials: a collusion of misunderstanding. Hastings Cent Rep 2000;30:34-43.
4. Appelbaum PS, Roth LH, Lidz CW, et al. False hopes and best data: consent to research and the therapeutic misconception. Hastings Cent Rep 1987;17:20-4.
5. Appelbaum PS, Lidz CW, Grisso T. Therapeutic misconception in clinical research: frequency and risk factors. IRB 2004;26:1-8.
6. Horng S, Grady C. Misunderstanding in clinical research: distinguishing therapeutic misconception, therapeutic misestimation, and therapeutic optimism. IRB 2003;25:11-16.
7. Jansen LA. The problem with optimism in clinical trials. IRB 2006;28:13-19.
8. Pentz RD, White M, Harvey RD, et al. Therapeutic misconception, misestimation, and optimism in participants enrolled in phase 1 trials. Cancer 2012;118:4571-8.
9. Daugherty C, Ratain MJ, Grochowski E, et al. Perception of cancer patients and their physician involved in phase 1 trials. J Clin Oncol 1995;13:1062-72.
10. Daugherty CK, Banik DM, Janish L, et al. Quantitative analysis of ethical issues in phase 1 trials: a survey interview of 144 advanced cancer patients. IRB 2000;22:6-14.
11. Meropol NJ, Weinfurt KP, Burnett CB, et al. Perceptions of patients and physicians regarding phase 1 cancer clinical trials: implications for physician-patient communication. J Clin Oncol 2003;13:2589-96.
12. Kass N, Sugarman J, Taylor H, et al. Purpose and benefits of early phase cancer trials: What do oncologists say? What do patients hear? J Empirical Res Hum Res Ethics 2008;3:57-68.
13. Jansen LA, Appelbaum PS, Klein WMP, et al. Unrealistic optimism in early-phase oncology trials. IRB 2011;33:1-8.
14. Brock DW. Philosophical justifications of informed consent. In: Emanuel EJ, Crouch RA, Grady C, Lie R, Miller FG, Wendler D, eds. The Oxford Textbook of Clinical Research Ethics. New York: Oxford University Press 2008:606-12.
15. Miller FG, Wertheimer A. The fair transaction model of informed consent: an alternative to autonomous authorization. Kennedy Inst Ethics J 2011;21:201-18.
16. Kahneman D. Thinking, Fast and Slow. New York: Farrar, Strauss and Giroux, 2011.
17. Beauchamp TL, Childress JF. Principles of biomedical ethics. 6th edn. New York: Oxford University Press, 2009:99-135.
18. Agrawal M, Grady C, Fairclough DL, et al. Patients' decision-making process regarding participation in phase 1 oncology research. J Clin Oncol 2006;24:4479-84.
19. King NMP. Defining and describing benefit appropriately in clinical trials. J Law Med Ethics 2000;28:332-43.
20. Sankar P. Communication and miscommunication in informed consent to research. Med Anthropol Q 2004;18:429-46.
21. Miller FG, Joffe S. Benefit in phase 1 oncology trials: therapeutic misconception or reasonable treatment option? Clinical Trials 2008;5:617-23.
22. Horstmann E, McCabe MS, Grochow L, et al. Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med 2005;352:895-904.
23. Joffe S, Miller FG. Rethinking risk-benefit assessment for phase I cancer trials. J Clin Oncol 2006;24:2987-90.
24. Kass NE, Sugarman J, Medley AM, et al. An intervention to improve cancer patients' understanding of early-phase clinical trials. IRB 2009;31:1-10.
25. Buchanan A, Brock DW. Deciding for others: the ethics of surrogate decision making. New York: Cambridge University Press, 1990:77.